Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
HPV-16/18 E6/E7-Specific T Lymphocytes Relapsed HPV-Associated Cancers HESTIA

lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma

  • 10 views
  • 27 Jan, 2021
  • 1 location
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter

busulfan
hla typing
chemotherapy regimen
estimated creatinine clearance
graft versus host disease
  • 3 views
  • 18 Jul, 2021
  • 2 locations
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

> Recipients will have: More bone marrow and a small fragment of bone removed Dental, diet, and social worker consultations Scans Chemotherapy and antibody therapy

lymphoproliferative disorder
hla typing
neutropenia
mycophenolate mofetil
schwartz
  • 138 views
  • 01 Aug, 2021
  • 2 locations
Regorafenib With Cetuximab or Panitumumab for the Treatment of Unresectable Locally Advanced or Metastatic Colorectal Cancer

This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic). Regorafenib …

  • 0 views
  • 16 Jun, 2021
  • 16 locations
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.

carcinoma
squamous cell carcinoma
ct scan
cancer
oropharyngeal squamous cell carcinoma
  • 48 views
  • 23 May, 2021
  • 14 locations
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

In this phase II study, study subjects will receive the VRP-HER2 immunizations plus pembrolizumab. There will be an initial Safety Arm during which subjects will receive the VRP-HER2 immunizations plus pembrolizumab. If there is no dose limiting toxicity in the Safety Arm, then subjects will be randomized into 3 arms. …

pertuzumab
trastuzumab
HER2
metastasis
mammogram
  • 5 views
  • 26 Jan, 2021
  • 1 location
A Study of IMU-201 (PD1-Vaxx) a B-Cell Immunotherapy in Adults With Non-Small Cell Lung Cancer

The phase 1 study is an open label, multi-center, non-randomized, dose escalation and expansion study designed to assess the safety, tolerability, and immunogenicity of IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC).

large cell carcinoma
platelet count
kidney function test
adenocarcinoma
lung cancer
  • 1 views
  • 28 May, 2021
  • 7 locations
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

  • 0 views
  • 17 Jun, 2021
  • 6 locations
Tolebrutinib a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Background Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These lesions can lead to slow worsening of MS symptoms. Researchers want to see if a new drug can help. Objective To see if tolebrutinib …

MRI
rituximab
ocrelizumab
  • 0 views
  • 28 Jul, 2021
  • 1 location
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, for proficient mismatch repair(pMMR)/microsatellite stable(MSS) CRC, the curative effect of PD-1 monoclonal antibody was poor and most of the data came from stage patients with distant metastasis. Among the whole CRC patients, …

  • 0 views
  • 29 May, 2021
  • 1 location